Feto-maternal indicators of cardiac dysfunction as a justification for the cardiac origins for pre-eclampsia

Kelly M Reilly1, Chris Watson2, Mark Ruddock3

  • 1Center for Public Health, Queens University Belfast, Belfast, UK.

Insights

Pre-eclampsia may originate from cardiac issues, not just placental problems. Research reviews biophysical and biochemical markers of cardiac dysfunction, revealing shared pathways with pre-eclampsia.

Area of Science:

  • Cardiovascular Medicine
  • Obstetrics
  • Genetics

Background:

  • Pre-eclampsia pathophysiology is debated, with placental dysfunction as a traditional theory.
  • A cardiac origin for pre-eclampsia is increasingly proposed.
  • An association exists between fetal congenital cardiovascular disease and pre-eclampsia, but mechanisms are unclear.

Purpose of the Study:

  • To review biophysical and biochemical markers of cardiac dysfunction in maternal and fetal cardiac disease.
  • To identify overlaps between these markers and predictors of pre-eclampsia.
  • To explore common pathophysiologic mechanisms linking cardiovascular disease and pre-eclampsia.

Main Methods:

  • Review of current literature on biophysical markers (echocardiography, Doppler indices).
  • Review of current literature on biochemical markers (proteomic, metabolomic, genetic/transcriptomic).
  • Analysis of shared pathways including inflammation, anti-angiogenesis imbalance, endothelial damage, and oxidative stress.

Main Results:

  • Identified various biophysical and biochemical markers of cardiac dysfunction.
  • Highlighted overlaps between cardiac dysfunction markers and pre-eclampsia predictors.
  • Demonstrated common underlying pathways in cardiovascular disease and pre-eclampsia.

Conclusions:

  • Cardiac dysfunction may play a significant role in pre-eclampsia.
  • Shared inflammatory, anti-angiogenic, endothelial, and oxidative stress pathways link cardiovascular disease and pre-eclampsia.
  • Further investigation into these common pathways is crucial for understanding the pathophysiology.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
74
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
134